A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer Wit
A phase 2 trial of Mirvetuximab soravtansine in ovarian cancer, run by AbbVie, active and no longer recruiting.
Overview
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression is a phase 2 interventional study registered as NCT06365853 by AbbVie, with 108 participants enrolled, started 2024-07-29 and due to reach its primary completion in 2027-02. Interventions recorded: Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops, Brimonidine tartrate ophthalmic solution eye drops. Conditions listed: Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialMirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ov
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialA Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult
Shares Mirvetuximab soravtansine, AbbVie (incl. ImmunoGen, Capstan), Ovarian cancer.
- TrialA Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Shares Mirvetuximab soravtansine, Ovarian cancer.
- TrialMirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C
- TrialA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1
- TrialMirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
Shares Mirvetuximab soravtansine, Ovarian cancer.